Education
About Us
Working with TipRanks
Follow Us
Revolution Medicines (RVMD)
NASDAQ:RVMD
Earnings Data
Report Date
Nov 05, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-1.41Last Year’s EPS
-0.94Same Quarter Last Year
Strong Buy
Based on 16 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a generally positive outlook with significant progress in clinical trials and strategic financial partnerships. However, increased expenses and dependency on regulatory approvals present challenges.Company Guidance
Breakthrough Therapy Designation for Daraxonrasib
Daraxonrasib received Breakthrough Therapy designation from the FDA for previously treated metastatic pancreatic cancer with KRAS G12 mutations, underscoring the large unmet medical needs for these patients.
Strong Progress in Clinical Trials
Significant progress in enrolling and advancing various clinical trials, including the global Phase III trial RASolute 302 and the upcoming registrational trials for daraxonrasib in first-line metastatic pancreatic cancer and as adjuvant treatment.
Financial Partnership with Royalty Pharma
RevMed has secured a $2 billion partnership with Royalty Pharma, providing flexible capital to support clinical development and commercialization without equity dilution.
Collaborations to Enhance Drug Discovery
Significant collaborations with companies like Aethon and Iambic to enhance discovery efforts through novel bispecific antibodies and AI capabilities.
RVMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RVMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 06, 2025 | $36.67 | $34.95 | -4.69% |
May 07, 2025 | $37.66 | $41.91 | +11.29% |
Feb 26, 2025 | $40.50 | $39.08 | -3.51% |
Nov 06, 2024 | $59.42 | $59.10 | -0.54% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Revolution Medicines (RVMD) report earnings?
Revolution Medicines (RVMD) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).
What is Revolution Medicines (RVMD) earnings time?
Revolution Medicines (RVMD) earnings time is at Nov 05, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RVMD EPS forecast?
RVMD EPS forecast for the fiscal quarter 2025 (Q3) is -1.41.
